|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Nephrology, Leiden University
Medical Center, The Netherlands.
Rapamycin (Rapa), a recently introduced immunosuppressive drug,
seems to be effective in preventing acute allograft rejection. Although
its antiproliferative effect on T lymphocytes has been investigated
extensively, its effect on the initiators of the immune response, the
dendritic cells (DCs), is not known. Therefore, the effect of Rapa on
monocyte- (mo-DCs) and CD34+-derived DCs in vitro but also
on other myeloid cell types, including monocytes and macrophages, was
examined. The present study shows that Rapa does not affect phenotypic
differentiation and CD40L-induced maturation of mo-DCs. However, Rapa
dramatically reduced cell recovery (40%-50%). Relatively low
concentrations of Rapa (10 Dendritic cells (DCs) are professional
antigen-presenting cells that are specialized in the uptake of antigens
and their transport from peripheral tissues to the lymphoid organs.
Because of their capacity to stimulate naive T cells, DCs have a
central role in the initiation of primary immune
responses.1 Human DCs can be grown in vitro from
CD34+ progenitors in medium supplemented with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor
necrosis factor- DCs are thought to play a critical role in diverse facets of immune
regulation, ranging from tolerance induction and the prevention of
autoimmunity to the induction of antitumor immunity and the protection
against infectious agents.1,7-9 A similar dichotomy of DC
functions has been proposed to play a role in allograft transplantation. Various experimental models have demonstrated that DCs
are critical for the induction of transplant
tolerance.10-13 As a consequence DCs have been genetically
modified to promote their tolerogenic potential.14 On the
other hand, it is clear that the immunostimulatory potential of DCs may
also contribute to disease pathogenesis of allograft
rejection.15 Donor DCs transplanted en bloc with the
allograft migrate to the recipient spleen,16 where they
can activate naive T lymphocytes, thereby inducing an immune response
via the direct pathway of allorecognition.17 Several
studies showed that preventing the direct pathway of allorecognition by
DC depletion resulted in prolonged graft survival.18-21 In
addition, both transplant injury and local inflammation will attract
recipient DCs to the graft,22 which contributes to the
indirect pathway of antigen presentation.17 Especially for
chronic rejection, it is thought that this indirect pathway plays a
critical role. Therefore, DCs might be an important target for
immunosuppression to prevent allograft rejection.
Activated T cells, rather than DCs, have been considered the main
targets for immunosuppression after transplantation. Immunosuppressive drugs like calcineurin inhibitors (cyclosporin A [CsA] and FK506) and
corticosteroids all have profound effects on T-cell activation. Recently, it has been shown that corticosteroids can also inhibit the
differentiation and maturation of DCs.23-25 This is in
contrast to the calcineurin inhibitors, which only have minor effects
on DC function.25-27 Despite good short-term effects for
graft survival, current immunosuppression shows limited impact on the
incidence of chronic allograft rejection and is characterized by
serious side effects. Therefore, there is still a need for the
development of alternative drugs.11
Rapamycin (Rapa), a macrolide antibiotic produced by Streptomyces
hygroscopicus,28 has been introduced recently as a
new effective drug for the prevention of allograft
rejection.29-31 Like CsA and FK506, Rapa exerts its
effects by binding to immunophilins and interference in the signaling
pathways involved in T-lymphocyte proliferation.32 Rapa is
structurally related to FK506, and it binds to and competes with FK506
for the same immunophilin FKBP-12. However, only the Rapa-FKBP
complex binds and inhibits the function of the serine/threonine kinase
mTOR (mammalian target of rapamycin),33,34 which is
involved in protein synthesis and cell cycle progression.
Whereas the effects of Rapa are well investigated with respect to the
effect on T lymphocytes, the effect of Rapa on antigen-presenting cells
is not known. Therefore, we investigated the effect of Rapa on myeloid
cell types, including monocytes, macrophages, and monocyte- and
CD34+- derived DCs, with respect to differentiation,
proliferation, and cell survival. The present study demonstrates that
Rapa specifically induces apoptosis in DCs without affecting
differentiation and maturation of these cells.
Reagents
Cell lines
Generation of dendritic cells Monocyte-derived DCs.
Monocyte-derived DCs (mo-DCs) were generated as described
before.25 In brief, human monocytes were isolated from
buffy coats obtained from healthy donors using Ficoll-Hypaque (Sigma)
and Percoll (Pharmacia, Uppsala, Sweden) density gradient
centrifugation, followed by plastic adherence (2 hours). DCs were
generated in 6-well culture plates (Costar, Cambridge, MA) in RPMI 1640 containing 10% CD34+-derived DCs.
CD34+ hematopoietic progenitor cells were isolated from
umbilical cord blood samples and used in cultures to generate immature DCs as previously described.3 In brief, CD34+
cells were isolated from mononuclear fractions through positive selection using anti-CD34-coated microbeads and Midi-Macs separation columns (both from Miltenyi Biotec, Bergish Gladbach, Germany). After
cryopreservation, cells were cultured in RPMI 1640 containing 10%
Macrophages Alveolar macrophages.
Human alveolar macrophages were isolated from bronchoalveolar lavage
fluid collected from patients who underwent bronchoalveolar lavage for
diagnostic reasons and who had no underlying pathological condition in
the lung segment from which the lavage fluid was obtained. The cells
were seeded in RPMI 1640 supplemented with 10% Monocyte-derived macrophages.
Monocytes were isolated from buffy coats as described above and
subsequently cultured for 7 days in RPMI 1640 containing 10% Activation of mo-DCs Six-day immature mo-DCs were activated with CD40L. CD40L activation was performed with CD40L-transfected L cells (L-CD40L)35 in a DC:L cell ratio of 4:1. Nontransfected L cells served as control cells (L-Orient). For stimulation, cells were incubated at 0.5 × 106 per well in 24-well plates (Costar) in the presence of IL-4 (10 ng/mL) and GM-CSF (5 ng/mL). Cells were analyzed by flow cytometry after 48 hours.Analysis of cell surface phenotype by flow cytometry Cells were harvested and washed in buffer containing 1% BSA, 1% heat-inactivated normal human serum (NHS, Bloodbank, Leiden, The Netherlands), and 0.02% NaN3. Fluorescence-activated cell sorter (FACS) analysis was performed using monoclonal antibodies against the following surface markers: CD1a (Leu-6) and CD14 (Leu-M3) (both Becton Dickinson, San Jose, CA), CD80 (monoclonal antibody 104), CD83 (HB15A; Immunotech, Marseille, France), CD86 (IT2.2; Pharmingen, San Diego, CA), HLA-ABC (w6/32; American Type Culture Collection, Rockville, MD), and HLA-DR (clone B8.11,2). Staining was visualized by using phycoerythrin-conjugated goat-anti-mouse immunoglobulin (Dako, Glostrup, Denmark). Fluorescein isothiocyanate (FITC)-conjugated anti-CD1a (Pharmingen) and phycoerythrin-conjugated anti-CD14 (Leu-M3; Becton Dickinson, San Jose, CA) antibodies were used for double staining of CD34+-derived DCs. The cells were assessed for fluorescence using a FACScan. Data acquisition was performed using Lysis-II software (Becton Dickinson, Mountain View, CA).Induction and detection of apoptosis Apoptosis induction experiments were performed in 6- or 24-well culture plates (Costar). CD34-derived DCs, U937, THP-1, MonoMac6, KG-1, Jurkat (all 2 × 105 cells/mL) and peripheral blood monocytes, alveolar macrophages, monocyte-derived macrophages, and mo-DCs (all 3 × 105 cells/mL) were cultured as described above. Cells were treated with several agents for 48 hours unless indicated otherwise, harvested, and assayed for apoptosis.To determine the morphologic nuclear changes, cells were harvested and fixed with 4% paraformaldehyde on ice. Cytospin preparations were made and stained with Hoechst 33258 (Molecular Probes, Leiden, The Netherlands) for 3 minutes at room temperature. The percentage of apoptotic cells was determined by examining 200 cells and counting the cells that were characterized by nuclear condensation and fragmentation. Phosphatidylserine exposure was determined using annexin V-FITC
(Apoptest FITC kit, Nexins Research, Kattendijke, The Netherlands) in
combination with propidium iodide (PI; Molecular Probes). Cells were
harvested, washed, labeled with annexin V-FITC for 30 minutes on ice,
and subsequently taken up in 1 µg/mL PI. Annexin V/PI staining was
conducted on a FACScan and analyzed using Lysis-II software. Data are
expressed as percentage of annexin V+ cells in the
PI Cell cycle analysis Cells were harvested, washed in 1 mM ethylenediaminetetraacetic acid/phosphate-buffered saline, and fixed in 90% ethanol for at least 30 minutes at 20°C. The cells were then washed and cellular DNA was
stained by treating the cells with 50 µg/mL RNase A (Sigma) and 10 µg/mL PI (Molecular Probes) for 45 minutes at room temperature. Fluorescence intensity was quantified on a per cell basis by FACScan.
Reduced cell yield after mo-DC development in the presence of Rapa The effect of Rapa on the differentiation of monocytes into mo-DCs was studied by culturing monocytes in the presence of IL-4 and GM-CSF with or without addition of Rapa (10 7 M). After 6 days of
culture, both nontreated and Rapa-treated cells displayed morphologic
and phenotypical characteristics of DCs. DCs generated in the presence
of Rapa showed a relatively low expression of costimulatory and HLA
molecules, were positive for CD1a, and were completely negative for
CD14 and CD83, as assessed by FACS analysis (Figure
1). Activation (48 hours) of these cells with CD40L induced the expression of CD83 and increased the expression of major histocompatibility complex class I, major histocompatibility complex class II, and costimulatory molecules (CD80, CD86) comparable to control DCs (Figure 1).
Although Rapa did not affect the phenotype of mo-DCs, viable cell yield
at day 6 of culture was 40% to 50% reduced, as assessed by trypan
blue exclusion (Figure 2). The
immunosuppressive drugs dexamethasone, CsA, or FK506 had only a minor
effect on cell recovery (> 86% compared with control).
Rapa induces apoptosis in immature mo-DCs but not in monocytes To examine whether Rapa reduced cell recovery by inducing cell death at the start of culture, freshly isolated monocytes were treated with Rapa for 48 hours. Monocyte cultures, without or with the addition of GM-CSF and IL-4, did not show Rapa-induced apoptosis assessed by either Hoechst (data not shown) or annexin V/PI staining (Figure 3A). In contrast, treatment of mo-DCs that were generated following the standard 6-day differentiation condition and subsequently treated with Rapa for 48 hours demonstrated a significant degree of apoptosis as shown by an increased phosphatidyl exposure using annexin V-FITC (Figure B), an increased nuclear condensation and fragmentation using Hoechst (Figure 3C), and an increased sub-G0 fraction using DNA staining (Figure 3D). Notably, all mo-DCs are in G0/G1 phase as expected in this nonproliferating cell population.
Kinetic experiments revealed that limited apoptosis of mo-DCs was
observed after 24-hour incubation with Rapa, which strongly increased
after 48 hours (Figure 4). Rapa-induced
apoptosis was already observed with 10
The observed difference between monocytes and mo-DCs suggests that
sensitivity to Rapa-induced apoptosis is acquired during differentiation. Daily analysis demonstrated that Rapa sensitivity becomes apparent between day 2 and 3 of differentiation (Figure 5).
Antagonistic effect of FK506 on Rapa-induced apoptosis Because FK506 and Rapa both bind to FKBP-12, they can act as reciprocal antagonists in systems where only one drug is active.36,37 Different concentrations of Rapa were added to immature mo-DCs in the presence of varying concentrations of the calcineurin inhibitor FK506 or CsA. At least a 10-fold excess of FK506 completely blocked Rapa-induced apoptosis, whereas even 100-fold excess of CsA showed no effect (Figure 6A).
Delayed addition of FK506 until 24 hours after the start of Rapa treatment still induced complete inhibition of apoptosis (Figure 6V). This implies that Rapa is reversibly associated with FKBP-12 and that the existence of this complex is required for more than 24 hours to induce strong apoptosis in mo-DCs. Rapa-induced apoptosis is partially caspase dependent Next, the involvement of caspase activation in Rapa-induced apoptosis was investigated. Addition of the general caspase inhibitor ZVAD caused a diminished Rapa-induced apoptosis in mo-DCs, as demonstrated by annexin V/PI staining (Figure 7) or when analyzed by Hoechst staining (data not shown). The level of inhibition by ZVAD was variable (range 5%-95%), suggesting both caspase-dependent and caspase-independent mechanisms of apoptosis.
Rapa induces apoptosis in CD34-derived DCs Next, we tested Rapa on CD34+ cells and on DCs derived from CD34+ precursors. Addition of Rapa to CD34+ cells prevented the strong proliferation, which normally occurs in the first 6 days of culture (Figure 8A). This block in proliferation was accompanied by a hampered development of CD14+ and CD1a+ DC populations (Figure 8B).
When normal CD34+-derived DCs at day 6 of culture were exposed to 100 nM Rapa, apoptosis could already be detected after 15 hours of incubation (Figure 8C). After 38 hours of incubation, the percentage of annexin V+ cells increased, mainly found within the PI+ population as a sign of late apoptotic cells (Figure 8C). Rapa selectively affects DCs but does not influence cell viability or cell cycle progression of other myeloid cell types To investigate whether Rapa specifically affects DCs, its effect was also tested on other myeloid cells. Monocyte-derived macrophages, alveolar macrophages, U937, THP-1, MonoMac6, KG-1, CD34+-derived DCs, and mo-DCs were incubated with Rapa or etoposide for 48 hours and subsequently analyzed for apoptosis (Table 1). Rapa, which was tested in a concentration range of 109 M to 106 M, was
not able to induce apoptosis in any of the myeloid cells tested, except
for the DCs. Also, stimulation of freshly isolated monocytes or U937
cells with interferon- did not induce Rapa sensitivity (data not
shown). Etoposide caused apoptosis in all cell lines but not in the
nonproliferating primary cells.
Because Rapa induces a G1 arrest in T cells, we
analyzed cell cycle progression in myeloid cell lines. As a positive
control, exposure of Jurkat to Rapa resulted in an accumulation of
cells in the G0/G1 phase but no increase in the
sub-G0 fraction (Figure 9,
Table 1). In contrast, the cell cycle of U937 (Figure 9) or any of the
other myeloid cell lines (Table 1) was not affected by treatment with
Rapa.
This is the first study demonstrating that Rapa can evoke apoptosis in human DCs. Both the monocyte-derived as well as the CD34+-derived DCs underwent strong apoptosis in the presence of Rapa in a time- and dose-dependent manner. Interestingly, monocytes, macrophages, either monocyte-derived or freshly isolated alveolar macrophages, and myeloid cell lines were completely insensitive for Rapa-induced apoptosis. Furthermore, the antiproliferative effect of Rapa, as shown using Jurkat cells, was absent when using the myeloid cell lines. This suggests a unique action of Rapa on some but not all myeloid cells. Rapa causes a G1-phase cell cycle arrest in T lymphocytes and some other cell types.34,38-41 In these cases Rapa complexes with FKBP-12, thereby inhibiting the serine/threonine kinase activity of mTOR and subsequent growth factor-induced protein synthesis and cell cycle progression.42-46 Translation of proteins important in cell cycle progression, such as cyclin D1, has been shown especially to be a target of mTOR function.46-48 In addition, the Rapa-induced increase in the expression of Cdk inhibitor p27 (KIP1) regulates G1-phase cell cycle arrest.49 Growing evidence suggests that apoptosis is frequently associated with cells in the G1 phase of the cell cycle, and arrest in late G1 or S phase can accelerate or induce apoptosis. Interestingly, the effect of Rapa we demonstrate on DCs seems to be independent of cell cycle regulation because mo-DCs are nonproliferating. Nevertheless, the activity of Rapa is dependent on prolonged interaction with FKBP-12 as shown by the antagonistic effect of FK506. Thus, the mechanism used by Rapa-FKBP complexes to induce apoptosis in DCs still has to be elucidated. A proapoptotic effect of Rapa has been demonstrated on murine T cells,50 human B lymphoma cells,51 and rhabdomyosarcoma cells.42 However, in all these studies apoptosis had to be induced by other signals, such as cytotoxic agents, which was further augmented by Rapa. In those cases, no information is provided about the mechanism of apoptosis. In the present study, we show that apoptosis is partially dependent on caspase activation. However, we also clearly identified a caspase-independent pathway. Recently, a number of other situations, including HLA-DR-mediated apoptosis of DCs, has been described in which caspase-independent apoptosis occurs.52-55 At present, immunosuppression used to prevent allograft rejection includes a combination of corticosteroids with a calcineurin inhibitor such as CsA. Despite the benefits of CsA in the prevention of acute rejection, it appears to have little impact on chronic graft loss. The latter might be caused by the fact that treatment with high doses of CsA prevents T-lymphocyte apoptosis and tolerance induction56 or by the fact that calcineurin inhibitors CsA and FK506 are nephrotoxic.57,58 Rapa is a powerful immunosuppressive drug that is not nephrotoxic. In a model of heart transplantation, Rapa, but not CsA, enhances apoptosis of activated T cells, which allows the induction of peripheral tolerance.59 Therefore, several clinical trials are focused on a combination therapy of Rapa and relatively low doses of calcineurin inhibitors.60,61 In those studies, Rapa is administered in higher doses than FK506, which prevents possible antagonism because FK506 has to be given in at least a 10-fold excess to reach a complete antagonistic effect. The fact that Rapa, next to the antiproliferative effect on T cells, selectively induces apoptosis in DCs might interrupt effective presentation of alloantigens to naive T cells and, thereby, initiation of an alloimmune response both by the direct and indirect pathway. Although the exact mechanism of Rapa-induced apoptosis and the importance in vivo has to be elucidated, induction of DC apoptosis might contribute to the unique actions of Rapa in the prevention of allograft rejection and other immune responses.
The authors thank the collaborators of the Department of Pulmonology (Leiden University Medical Center) for providing human alveolar macrophages, C. Massacrier (Laboratory of Immunological Research, Schering-Plough, Dardilly, France) and A. B. Kruisselbrink (Leiden University Medical Center) for technical assistance, and C. Caux and F. Briere (Schering-Plough) for critical discussions about this manuscript.
Submitted September 19, 2000; accepted March 12, 2001.
C.v.K. is a fellow of the Royal Netherlands Academy of Arts and Sciences.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Cees van Kooten, LUMC, Dept of Nephrology, C3-P, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; e-mail: kooten{at}lumc.nl.
1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252[CrossRef][Medline] [Order article via Infotrieve]. 2. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature. 1992;360:258-261[CrossRef][Medline] [Order article via Infotrieve].
3.
Caux C, Massacrier C, Vanbervliet B, et al.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha, II: functional analysis.
Blood.
1997;90:1458-1470
4.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J Exp Med.
1994;179:1109-1118
5.
Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA.
Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking.
Science.
1998;282:480-483 6. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 1999;11:753-761[CrossRef][Medline] [Order article via Infotrieve]. 7. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811[CrossRef][Medline] [Order article via Infotrieve]. 8. Drakesmith H, Chain B, Beverley P. How can dendritic cells cause autoimmune disease? Immunol Today. 2000;21:214-217[CrossRef][Medline] [Order article via Infotrieve]. 9. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-273[CrossRef][Medline] [Order article via Infotrieve].
10.
Josien R, Heslan M, Brouard S, Soulillou JP, Cuturi MC.
Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion.
Blood.
1998;92:4539-4544 11. Waldmann H. Transplantation tolerance-where do we stand? Nat Med. 1999;5:1245-1248[CrossRef][Medline] [Order article via Infotrieve]. 12. Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today. 1999;20:27-32[CrossRef][Medline] [Order article via Infotrieve].
13.
Sallusto F, Lanzavecchia A.
Mobilizing dendritic cells for tolerance, priming, and chronic inflammation [comment].
J Exp Med.
1999;189:611-614 14. Lu L, Lee WC, Takayama T, et al. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). J Leukoc Biol. 1999;66:293-296[Abstract]. 15. Thomson AW, Lu L. Dendritic cells as regulators of immune reactivity: implications for transplantation. Transplantation. 1999;68:1-8[Medline] [Order article via Infotrieve].
16.
Larsen CP, Morris PJ, Austyn JM.
Migration of dendritic leukocytes from cardiac allografts into host spleens: a novel pathway for initiation of rejection.
J Exp Med.
1990;171:307-314 17. Gould DS, Auchincloss HJ. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today. 1999;20:77-82[CrossRef][Medline] [Order article via Infotrieve]. 18. McKenzie JL, Beard ME, Hart DN. Depletion of donor kidney dendritic cells prolongs graft survival. Transplant Proc. 1984;16:948-951[Medline] [Order article via Infotrieve].
19.
Lechler RI, Batchelor JR.
Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells.
J Exp Med.
1982;155:31-41 20. Goldberg LC, Bradley JA, Connolly J, et al. Anti-CD45 monoclonal antibody perfusion of human renal allografts prior to transplantation: a safety and immunohistological study. CD45 Study Group. Transplantation. 1995;59:1285-1293[Medline] [Order article via Infotrieve]. 21. Krzymanski M, Waaga AM, Ulrichs K, et al. The influence of MHC class II antigen blockade by perfusion with a monoclonal antibody on rat renal graft survival. Transpl Int. 1991;4:180-185[CrossRef][Medline] [Order article via Infotrieve]. 22. Penfield JG, Wang Y, Li S, et al. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney. Kidney Int. 1999;56:1759-1769[CrossRef][Medline] [Order article via Infotrieve]. 23. Moser M, De Smedt T, Sornasse T, et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol. 1995;25:2818-2824[Medline] [Order article via Infotrieve].
24.
Rea D, Van Kooten C, van Meijgaarden KE, Ottenhoff TH, Melief CJ, Offringa R.
Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10.
Blood.
2000;95:3162-3167 25. Woltman AM, Fijter JW, Kamerling SWA, Paul LC, Daha MR, Van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol. 2000;30:1807-1812[CrossRef][Medline] [Order article via Infotrieve]. 26. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation. 1999;68:1255-1263[Medline] [Order article via Infotrieve]. 27. Peguet-Navarro J, Slaats M, Thivolet J. Lack of demonstrable effect of cyclosporin A on human epidermal Langerhans cell function. Arch Dermatol Res. 1991;283:198-202[CrossRef][Medline] [Order article via Infotrieve]. 28. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic, II: fermentation, isolation and characterization. J Antibiot. 1975;28:727-732[Medline] [Order article via Infotrieve]. 29. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999;68:1526-1532[CrossRef][Medline] [Order article via Infotrieve].
30.
Sacks SH.
Rapamycin on trial.
Nephrol Dial Transplant.
1999;14:2087-2089 31. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. N Engl J Med. 2000;356:194-202. 32. McKeon F. When worlds collide: immunosuppressants meet protein phosphatases. Cell. 1991;66:823-826[Medline] [Order article via Infotrieve].
33.
Sabers CJ, Martin MM, Brunn GJ, et al.
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
J Biol Chem.
1995;270:815-822 34. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69:1227-1236[CrossRef][Medline] [Order article via Infotrieve].
35.
Garrone P, Neidhardt EM, Garcia E, Galibert L, Van Kooten C, Banchereau J.
Fas ligation induces apoptosis of CD40-activated human B lymphocytes.
J Exp Med.
1995;182:1265-1273 36. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol. 1990;144:1418-1424[Abstract].
37.
Vilella-Bach M, Nuzzi P, Fang Y, Chen J.
The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
J Biol Chem.
1999;274:4266-4272
38.
Bierer BE, Mattila PS, Standaert RF, et al.
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.
Proc Natl Acad Sci U S A.
1990;87:9231-9235
39.
Calvo V, Crews CM, Vik TA, Bierer BE.
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin.
Proc Natl Acad Sci U S A.
1992;89:7571-7575 40. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 1992;358:70-73[CrossRef][Medline] [Order article via Infotrieve].
41.
Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE.
Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.
Science.
1992;257:973-977
42.
Hosoi H, Dilling MB, Shikata T, et al.
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer Res.
1999;59:886-894 43. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377:441-446[CrossRef][Medline] [Order article via Infotrieve].
44.
Chiu MI, Katz H, Berlin V.
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Proc Natl Acad Sci U S A.
1994;91:12574-12578 45. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35-43[CrossRef][Medline] [Order article via Infotrieve]. 46. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758[CrossRef][Medline] [Order article via Infotrieve]. 47. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134[CrossRef][Medline] [Order article via Infotrieve]. 48. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol. 1997;9:782-787[CrossRef][Medline] [Order article via Infotrieve]. 49. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573[CrossRef][Medline] [Order article via Infotrieve].
50.
Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB.
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Cancer Res.
1995;55:1982-1988 51. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264-270[Medline] [Order article via Infotrieve].
52.
Bertho N, Drenou B, Laupeze B, et al.
HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.
J Immunol.
2000;164:2379-2385
53.
Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA.
A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes.
J Immunol.
1999;163:4115-4124 54. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet. 1998;20:259-265[CrossRef][Medline] [Order article via Infotrieve].
55.
Deas O, Dumont C, MacFarlane M, et al.
Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes.
J Immunol.
1998;161:3375-3383 56. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 1999;5:1298-1302[CrossRef][Medline] [Order article via Infotrieve]. 57. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996;50:1089-1100[Medline] [Order article via Infotrieve]. 58. Abramowicz D, Wissing KM, Broeders N. Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches. Transplant Proc. 2000;32:3S-5S[Medline] [Order article via Infotrieve]. 59. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999;5:1303-1307[CrossRef][Medline] [Order article via Infotrieve]. 60. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355:376-377[CrossRef][Medline] [Order article via Infotrieve].
61.
Shapiro AM, Lakey JR, Ryan EA, et al.
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
N Engl J Med.
2000;343:230-238
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. M. Janelsins, A. R. Mathers, O. A. Tkacheva, G. Erdos, W. J. Shufesky, A. E. Morelli, and A. T. Larregina Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity Blood, March 26, 2009; 113(13): 3017 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zang, M. Lin, S. Kalache, N. Zhang, B. Kruger, A. M. Waaga-Gasser, M. Grimm, W. Hancock, P. Heeger, B. Schroppel, et al. Inhibition of the Alloimmune Response through the Generation of Regulatory T Cells by a MHC Class II-Derived Peptide J. Immunol., December 1, 2008; 181(11): 7499 - 7506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Reichardt, C. Durr, D. von Elverfeldt, E. Juttner, U. V. Gerlach, M. Yamada, B. Smith, R. S. Negrin, and R. Zeiser Impact of Mammalian Target of Rapamycin Inhibition on Lymphoid Homing and Tolerogenic Function of Nanoparticle-Labeled Dendritic Cells following Allogeneic Hematopoietic Cell Transplantation J. Immunol., October 1, 2008; 181(7): 4770 - 4779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kakazu, N. Kanno, Y. Ueno, and T. Shimosegawa Extracellular Branched-Chain Amino Acids, Especially Valine, Regulate Maturation and Function of Monocyte-Derived Dendritic Cells J. Immunol., November 15, 2007; 179(10): 7137 - 7146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cutler, S. Li, V. T. Ho, J. Koreth, E. Alyea, R. J. Soiffer, and J. H. Antin Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood, April 1, 2007; 109(7): 3108 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bauriedel, D. Skowasch, U. Welsch, and B. Luderitz Role of dendritic cells in specific atherosclerosis types Eur. Heart J., January 1, 2006; 27(1): 116 - 116. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takeuchi, Y. Kondo, K. Fujiwara, T. Kanzawa, H. Aoki, G. B. Mills, and S. Kondo Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors Cancer Res., April 15, 2005; 65(8): 3336 - 3346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Brown Morphoproteomic Analysis of Osteolytic Langerhans Cell Histiocytosis with Therapeutic Implications Ann. Clin. Lab. Sci., April 1, 2005; 35(2): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Nauta, G. Castellano, W. Xu, A. M. Woltman, M. C. Borrias, M. R. Daha, C. van Kooten, and A. Roos Opsonization with C1q and Mannose-Binding Lectin Targets Apoptotic Cells to Dendritic Cells J. Immunol., September 1, 2004; 173(5): 3044 - 3050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Woltman, N. Schlagwein, S. W. van der Kooij, and C. van Kooten The Novel Cyclophilin-Binding Drug Sanglifehrin A Specifically Affects Antigen Uptake Receptor Expression and Endocytic Capacity of Human Dendritic Cells J. Immunol., May 15, 2004; 172(10): 6482 - 6489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, C. E. N. Reiter, D. A. Antonetti, S. R. Kimball, L. S. Jefferson, and T. W. Gardner Insulin Promotes Rat Retinal Neuronal Cell Survival in a p70S6K-dependent Manner J. Biol. Chem., March 5, 2004; 279(10): 9167 - 9175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-H. Chiang, L. Wang, C. A. Bonham, X. Liang, J. J. Fung, L. Lu, and S. Qian Mechanistic Insights into Impaired Dendritic Cell Function by Rapamycin: Inhibition of Jak2/Stat4 Signaling Pathway J. Immunol., February 1, 2004; 172(3): 1355 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bell, X. Cao, J. A. Moibi, S. R. Greene, R. Young, M. Trucco, Z. Gao, F. M. Matschinsky, S. Deng, J. F. Markman, et al. Rapamycin Has a Deleterious Effect on MIN-6 Cells and Rat and Human Islets Diabetes, November 1, 2003; 52(11): 2731 - 2739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Steinschulte, T. Taner, A. W. Thomson, G. Bein, and H. Hackstein Cutting Edge: Sanglifehrin A, a Novel Cyclophilin-Binding Immunosuppressant Blocks Bioactive IL-12 Production by Human Dendritic Cells J. Immunol., July 15, 2003; 171(2): 542 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hackstein, T. Taner, A. F. Zahorchak, A. E. Morelli, A. J. Logar, A. Gessner, and A. W. Thomson Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo Blood, June 1, 2003; 101(11): 4457 - 4463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Woltman and C. van Kooten Functional modulation of dendritic cells to suppress adaptive immune responses J. Leukoc. Biol., April 1, 2003; 73(4): 428 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Woltman, S. W. van der Kooij, P. J. Coffer, R. Offringa, M. R. Daha, and C. van Kooten Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression Blood, February 15, 2003; 101(4): 1439 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsue, C. Yang, K. Matsue, D. Edelbaum, M. Mummert, and A. Takashima Contrasting Impacts of Immunosuppressive Agents (Rapamycin, FK506, Cyclosporin A, and Dexamethasone) on Bidirectional Dendritic Cell-T Cell Interaction During Antigen Presentation J. Immunol., October 1, 2002; 169(7): 3555 - 3564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hackstein, T. Taner, A. J. Logar, and A. W. Thomson Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells Blood, July 18, 2002; 100(3): 1084 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Woltman, C. Massacrier, J. W. de Fijter, C. Caux, and C. van Kooten Corticosteroids Prevent Generation of CD34+-Derived Dermal Dendritic Cells But Do Not Inhibit Langerhans Cell Development J. Immunol., June 15, 2002; 168(12): 6181 - 6188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson, M. H. Grayson, D. F. Osborne, T. H. Wagner, J. P. Cobb, C. Coopersmith, and I. E. Karl Depletion of Dendritic Cells, But Not Macrophages, in Patients with Sepsis J. Immunol., March 1, 2002; 168(5): 2493 - 2500. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) FCS and
penicillin/streptomycin (P/S) (all from Gibco/Life Technologies, Breda,
The Netherlands). The monocytic cell line MonoMac6 was cultured in RPMI
1640 supplemented with 10 µg/mL insulin, 10 µg/mL transferrin, 10 ng/mL selenium (all Sigma), 50 µM 
2-mercaptoethanol, 5% 
